Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18+
SponsorSheba Medical Center

About this trial

The goal of this clinical trial is to learn if the drug carbetocin works better than standard care to prevent heavy bleeding after childbirth in people carrying twin pregnancies. Heavy bleeding after delivery, also called postpartum hemorrhage, is more common after twin births and can lead to anemia, blood transfusions, and other serious health problems.

In this study, bleeding will be evaluated by measuring how much blood hemoglobin levels drop from before delivery to the day after delivery.

The main questions this study aims to answer are:

* Does giving carbetocin after delivery lower blood loss compared with standard oxytocin treatment? * Is carbetocin safe and practical to use in twin deliveries?

Researchers will compare carbetocin to standard oxytocin treatment to see which approach better prevents bleeding after twin vaginal or cesarean delivery.

Participants will:

* Be randomly assigned to receive either carbetocin or standard oxytocin after the second twin is delivered * Have blood tests before delivery and on the day after delivery * Be followed during their hospital stay and for up to six weeks after delivery for safety outcomes

Eligibility criteria

Qualifiers

Pregnant individuals aged ≥18 years

Twin pregnancies

Gestational age ≥23 weeks

Disqualifiers

Known hypersensitivity or contraindication to carbetocin

Higher-order multiple gestation (triplets or more)

Maternal age <18 years

Known placenta accreta spectrum

Trial design

Treatments tested in this trial

  • Carbetocin
  • Oxytocin

Treatment groups

120 Participants
are divided into 2 treatment groups

Sponsors and collaborators